DOI QR코드

DOI QR Code

Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC)

  • Wang, Jing-Luan (Department of Critical Care Medicine, Qilu Hospital, Shandong University) ;
  • Wu, Da-Wei (Department of Critical Care Medicine, Qilu Hospital, Shandong University) ;
  • Cheng, Zhao-Zhong (Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University) ;
  • Han, Wei-Zhong (Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University) ;
  • Xu, Sheng-Wei (Department of Respiratory Medicine, The Third People's Hospital of Qingdao) ;
  • Sun, Ni-Na (Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University)
  • Published : 2014.06.30

Abstract

Objective: This study evaluated the expression level of high mobility group box-B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC) inmorder to reveal any relation with development and prognosis. Methods: NSCLC and normal tissues were selected from 30 patients at age of 30-73, and used for RT-PCR and Western blot analyses of HMGB-1. A total of 100 paraffin embedded NSCLC tissues were also isolated from patients through surgical resection, and used for detection of HMGB-1 by immunohistochemistry. In addition, 50 samples were also applied for MMP-9 detection, and 30 normal tissues were considered as controls. Correlation analysis of HMGB-1 and MMP-9 was carried out by Pearsons correlation coefficient. Results: The average expression level of HMGB-1 in NSCLC patients was significantly higher than in normal lung tissues. In addition, patients in III-IV period exhibit significantly higher positive rate of HMGB-1 when compared with I-II period cases. Furthermore, a positive correlation with HMGB-1 was found in the expression of MPP-9. Conclusion: HMGB-1 was highly expressed in NSCLC, which may become a prognostic and predictive marker for NSCLC. Besides, MPP-9 was positively correlated with HMGB-1.

References

  1. Zheng Z, Chen T, Li X, et al (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New Engl J Med, 356, 800-8. https://doi.org/10.1056/NEJMoa065411
  2. Wu F, Zhao ZH, Ding ST, et al (2013). High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 5789-95. https://doi.org/10.7314/APJCP.2013.14.10.5789
  3. Yang H, Wang H, Czura CJ , Tracey K J (2005). The cytokine activity of HMGB1. J Leukocyte Biol, 78, 1-8. https://doi.org/10.1189/jlb.1104648
  4. Zhang QW, Liu L, Chen R, et al (2012). Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 2903-8. https://doi.org/10.7314/APJCP.2012.13.6.2903
  5. Stetler-Stevenson W, Liotta L , Kleiner D (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J, 7, 1434-41. https://doi.org/10.1096/fasebj.7.15.8262328
  6. Simon G R, Sharma S, Cantor A, et al (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. CHEST Journal, 127, 978-83. https://doi.org/10.1378/chest.127.3.978
  7. Sims GP, Rowe DC, Rietdijk ST, et al (2009). HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol, 28, 367-88.
  8. Song J, Su H, Zhou YY , Guo LL (2013). Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev, 14, 1615-21. https://doi.org/10.7314/APJCP.2013.14.3.1615
  9. Taguchi A, Blood DC, del Toro G, et al (2000). Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 405, 354-60. https://doi.org/10.1038/35012626
  10. Takada M, Hirata K, Ajiki T, et al (2004). Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology, 51, 928-30.
  11. Tsao MS, Aviel-Ronen S, Ding K, et al (2007). Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol, 25, 5240-7. https://doi.org/10.1200/JCO.2007.12.6953
  12. Volp K, Brezniceanu ML, Bosser S, et al (2006). Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut, 55, 234-42. https://doi.org/10.1136/gut.2004.062729
  13. Wang H, Yang H, Tracey K (2004). Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med, 255, 320-31. https://doi.org/10.1111/j.1365-2796.2003.01302.x
  14. Wang L, Wang Q, Li HL , Han LY (2013). Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma--relationship with prognosis. Asian Pac J Cancer Prev, 14, 2113-8. https://doi.org/10.7314/APJCP.2013.14.3.2113
  15. Park SI, Lee HR, Kim S, et al (2012). Time-sequential modulation in expression of growth factors from plateletrich plasma (PRP) on the chondrocyte cultures. Mol Cell Biochem, 361, 9-17. https://doi.org/10.1007/s11010-011-1081-1
  16. Miller VA, Riely G J, Zakowski M F, et al (2008). Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol, 26, 1472-8. https://doi.org/10.1200/JCO.2007.13.0062
  17. Nomoto K, Tsuta K, Takano T, et al (2006). Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol, 126, 608-15. https://doi.org/10.1309/N5PQNGW2QKMX09X7
  18. Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl J Med, 355, 983-91. https://doi.org/10.1056/NEJMoa060570
  19. Quint LE, Tummala S, Brisson LJ, et al (1996). Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg, 62, 246-50. https://doi.org/10.1016/0003-4975(96)00220-2
  20. Rodenhuis S, van de Wetering M L, Mooi W J, et al (1987). Mutational activation of the K-ras oncogene. New Engl J Med, 317, 929-35. https://doi.org/10.1056/NEJM198710083171504
  21. Salgia R (2011). Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer, 117, 3889-99. https://doi.org/10.1002/cncr.25935
  22. Sasahira T, Kirita T, Oue N, et al (2008). High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci, 99, 1806-12.
  23. Shang GH, Jia CQ, Tian H, et al (2009). Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Resp Med, 103, 1949-53. https://doi.org/10.1016/j.rmed.2009.05.019
  24. Kuniyasu H, Oue N, Wakikawa A, et al (2002). Expression of receptors for advanced glycation end, products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol, 196, 163-70. https://doi.org/10.1002/path.1031
  25. Gao XH, Yang XQ, Wang BC, et al (2013). Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. Asian Pac J Cancer Prev, 14, 5055-60. https://doi.org/10.7314/APJCP.2013.14.9.5055
  26. Goldstraw P, Ball D, Jett JR, et al (2011). Non-small-cell lung cancer. The Lancet, 378, 1727-40. https://doi.org/10.1016/S0140-6736(10)62101-0
  27. Klein T , Bischoff R (2011). Physiology and pathophysiology of matrix metalloproteases. Amino acids, 41, 271-90. https://doi.org/10.1007/s00726-010-0689-x
  28. Kuniyasu H, Yano S, Sasaki T, et al (2005). Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol, 166, 751-9. https://doi.org/10.1016/S0002-9440(10)62296-1
  29. Li LN, Zhou X, Gu Y, Yan J (2013). Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 4107-13. https://doi.org/10.7314/APJCP.2013.14.7.4107
  30. Lin ZM, Zhao JX, Duan XN, et al (2014). Effects of tissue factor, PAR-2 and MMP-9 expression on human breast cancer cell line MCF-7 invasion. Asian Pac J Cancer Prev, 15, 643-6. https://doi.org/10.7314/APJCP.2014.15.2.643
  31. Liu PL, Tsai JR, Hwang JJ, et al (2010).High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Resp Cell Mol, 43, 530-8. https://doi.org/10.1165/rcmb.2009-0269OC
  32. Maeda S, Hikiba Y, Shibata W, et al (2007). Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Bioph Res Co, 360, 394-400. https://doi.org/10.1016/j.bbrc.2007.06.065
  33. Mao XJ, Wang GF, Chen ZJ, et al (2012). Expression of HMGB1 and its clinical significance in T-cell lymphoma. Asian Pac J Cancer Prev, 13, 5569-71. https://doi.org/10.7314/APJCP.2012.13.11.5569
  34. Eberhard DA, Johnson BE, Amler LC, et al (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23, 5900-9. https://doi.org/10.1200/JCO.2005.02.857
  35. Bepler G, Sharma S, Cantor A, et al (2004). RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol, 22, 1878-85. https://doi.org/10.1200/JCO.2004.12.002
  36. Brezniceanu ML, Volp K, Bosser S, et al (2003). HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J, 17, 1295-7. https://doi.org/10.1096/fj.02-0621fje
  37. Dumitriu IE, Baruah P, Manfredi AA, et al (2005). HMGB1: guiding immunity from within. Trends Immunol, 26, 381-7. https://doi.org/10.1016/j.it.2005.04.009
  38. Ellerman JE, Brown CK, de Vera M, et al (2007). Masquerader: high mobility group box-1 and cancer. Clin Canc Res, 13, 2836-48. https://doi.org/10.1158/1078-0432.CCR-06-1953
  39. Ettinger D, Akerley W, Bepler G, et al (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6, 228. https://doi.org/10.6004/jnccn.2008.0021
  40. Ettinger DS, Akerley W, Bepler G, et al (2010). Non-small cell lung cancer. JNCCN, 8, 740-801.

Cited by

  1. Expression of RECK and MMPs in Hepatoblastoma and Neuroblastoma and Comparative Analysis on the Tumor Metastasis vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4007
  2. High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3693-7
  3. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma vol.36, pp.5, 2015, https://doi.org/10.1007/s13277-014-2997-3
  4. Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma vol.14, pp.1, 2017, https://doi.org/10.3892/ol.2017.6116